ILDR2 (internal designation CGEN-15001T) is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.
Studies testing the immune function of ILDR2, as a membrane bound protein or using a recombinant fusion protein containing the extracellular domain of ILDR2, showed it is capable of inhibiting T cell activation, promoting a Th1 to Th2 shift, and potentially inducing immune tolerance. ILDR2 is expressed in subpopulations of immune cells, mainly macrophages, in both tumor and normal tissue samples.
In August 2013, Compugen signed a research and discovery collaboration and license agreement with Bayer HealthCare for the development and commercialization of antibody-based therapeutics for cancer immunotherapy against ILDR2. After achieving all preclinical stage milestones, this program was transferred to Bayer for further development.
In April 2018, Bayer disclosed BAY 1905254, a novel immune checkpoint inhibitor for cancer immunotherapy targeting ILDR2. BAY 1905254 is a human/mouse cross-reactive antibody blocking the immunosuppressive activity of ILDR2. BAY 1905254 exhibits anti-tumor activity as a monotherapy in various mouse models, and was also shown to have additive anti-tumor effects in combination with other cancer therapy approaches in those models, indicating the possibility for multiple combination uses in cancer immunotherapy.
Bayer also announced in April 2018 its plans to advance the program into first-in-human trials in 2018.
To date, Compugen received from Bayer approximately $25 million in upfront and preclinical milestone payments. It is entitled to over $250 million in potential milestone payments and mid-to-high single digit royalties on global net sales.